论文部分内容阅读
立他司特(Lifitegrast)是一种新的细胞间黏附因子的抑制剂,可以通过阻断细胞间黏附分子-1和整合素蛋白淋巴细胞功能相关抗原-1之间的结合起效。2016年7月,美国食品药品管理局(FDA)正式批准了5%立他司特滴眼剂(商品名XiidraTM)的申请。该药的临床试验主要包括针对干眼症患者的1个为期12周的II期临床试验和3个为期12周的III期临床试验,研究结果充分证明了该药的有效性和安全性。立他司特是FDA批准的第一个可以改善和治疗干眼症症状的新药,其他类似药物只有环孢素,在不久的将来其临床应用会更加广泛。
Lifitegrast is a novel inhibitor of intercellular adhesion molecule that works by blocking the binding between intercellular adhesion molecule-1 and integrin-like lymphocyte function-associated antigen-1. In July 2016, the U.S. Food and Drug Administration (FDA) formally approved the application of 5% etanercept eye drops (XiidraTM). The drug’s clinical trials include a 12-week phase II clinical trial and three 12-week phase III clinical trial for patients with dry eye, the results of the study proved the effectiveness and safety of the drug. Stevestut is the first FDA-approved new drug to ameliorate and treat symptoms of dry eye. Cyclosporine is the only other drug of similar use, and its clinical utility will be broader in the near future.